Gilead Sciences Inc. (NASDAQ:GILD) hired Johanna Mercier as chief commercial officer, effective July 1, to assume the responsibilities of Laura Hamill, who is leaving nine months after joining the company as EVP of worldwide commercial...

Cancer detection company Grail Inc. (Menlo Park, Calif.) appointed Hal Barron and Hans Bishop to its board. Barron is CSO and president of R&D at GlaxoSmithKline plc (NYSE:GSK; LSE:GSK), and Bishop was president and CEO...

Cardiovascular, metabolic and pulmonary company Vivus Inc. (NASDAQ:VVUS) said CEO Seth Fischer will step down. Thomas King, a director, will serve as interim CEO as the company seeks a permanent replacement. King was president and...

Simultaneous publications from Eli Lilly and Co ., Johnson & Johnson and Novo Nordisk A/S identifying GFRAL as the receptor of the anti-obesity hormone GDF15 will undoubtedly accelerate therapeutic translation of the pathway. The race...

U.S. pricing pressure on insulin and hemophilia products have caused Novo Nordisk A/S to guide for negative sales and operating profit growth for the first time ever. While newly launched diabetes and obesity products are...

Earnings on deck At least five biotechs and pharmas are expected to report earnings this week. (A) Reported and estimated EPS for 12 months Company Date Pre/post mkt 4Q16 EPS est 4Q15 EPS Expected chg...

Selten granted Vivus exclusive, worldwide rights to develop and commercialize tacrolimus and ascomycin to treat pulmonary arterial hypertension (PAH) and related vascular diseases. Selten had rights to patents covering the drugs from Stanford University (Stanford,...

Earnings on deck At least 12 biotechs and pharmas are expected to report earnings this week. (A) Nine-month EPS; (B) Fiscal 2Q; (C) First half EPS Company Date Pre/post mkt 3Q16 EPS est 3Q15 EPS...

Vivus granted Mist’s Metuchen Pharmaceuticals LLC affiliate exclusive rights to commercialize erectile dysfunction drug Stendra avanafil in the U.S., Canada, South America and India. Vivus will receive $70 million up front. Metuchen will be responsible...

Declining HCV sales and lower guidance from Gilead Sciences Inc. (NASDAQ:GILD) shaved about $10 billion off the bellwether's market cap last Tuesday and renewed investor calls for the company to do a splashy deal to...